Treatment of advanced epithelial ovarian carcinoma in pregnancy with cisplatin-based chemotherapy

King, Lynda A.; Nevin, Phillip C.; Williams, Preston P.; Carson, Linda F.

doi:10.1016/0090-8258(91)90259-8

Cited by 71 publications

(27 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Furthermore, most of them are early-stage ovarian carcinomas or nonepithelial carcinomas, and advanced epithelial ovarian carcinomas are extremely rare. 3 This condition can represent a clinical dilemma in the choice between the best treatment for the mother and the preservation of fetal well-being. How long can we wait for maturity of the fetus?…”

Section: Shin-ichi Ishioka · Takuhiro Hayashi · Toshiaki Endo Tsuyoshmentioning

confidence: 99%

Advanced epithelial ovarian carcinoma during pregnancy

et al. 2007

View full text Add to dashboard Cite

We report a rare case of advanced ovarian mucinous adenocarcinoma in a pregnant woman. A 28-year-old pregnant Japanese woman was diagnosed with an ovarian tumor 8 cm in diameter at a local hospital. She was sent to a private hospital at 25 weeks of gestation because of the growing ovarian tumor. Advanced ovarian carcinoma with widespread intraabdominal dissemination was detected by laparotomy at the hospital and she was referred to our hospital for further management. At 27 weeks of gestation, she underwent cesarean section, followed by abdominal total hysterectomy, and bilateral salpingo-oophorectomy. A girl weighing 879 g was delivered, with Apgar scores of 4 and 6 at 1 and 5 min, respectively. The pathological diagnosis of the tumor was mucinous cystadenocarcinoma grade 2. Although chemotherapy was not effective for her and she died of the disease 4 months after the surgery, her baby grew well and weighed 3750 g 3 months after delivery. For the treatment of such patients, we believe we should choose operative therapy as early as possible after the maturation of the fetus, although there are several reports of successful treatment with the administration of chemotherapy during pregnancy. To determine a better approach for such patients, multidisciplinary staff meetings, including gynecological oncologists, obstetricians, neonatologists, psychologists, and the patient are important.

show abstract

Section: Shin-ichi Ishioka · Takuhiro Hayashi · Toshiaki Endo Tsuyoshmentioning

confidence: 99%

Advanced epithelial ovarian carcinoma during pregnancy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Cisplatin administered at 26 weeks of gestation was associated with neutropenia, hair loss, and some hearing impairment in a premature neonate who was delivered 6 days after being exposed [9]. Additional reports demonstrated that cisplatin was generally tolerated and not associated with toxicity in the newborn when used during the second and third trimesters [10][11][12]. There is, however, limited information on the use and risk of taxane therapy during pregnancy.…”

Section: Discussionmentioning

confidence: 88%

“…From the ninth week of unrecognized gestation, she received the first-line chemotherapy with docetaxel and cisplatin. The use of platinum during pregnancy has been described in not a few of reports [9][10][11][12]. Cisplatin administered at 26 weeks of gestation was associated with neutropenia, hair loss, and some hearing impairment in a premature neonate who was delivered 6 days after being exposed [9].…”

Section: Discussionmentioning

confidence: 93%

Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy

Kim

Sung

et al. 2008

Lung Cancer

View full text Add to dashboard Cite

“…If sonographic and clinical findings suggest benign disease, conservative management and ultrasound follow up of maternal cysts are sufficient [12] as a published study by Hill et al, reported that 14% of unilocular cysts resolve spontaneously [14]. However, surgical exploration should be considered if the cyst is greater than 6 cm, bilateral or persistent and has significant solid components on scan [15,16]. Between 10 and 15% of ovarian cysts will undergo torsion and cause pain, therefore requiring surgery, usually performed electively in the second trimester [17].…”

Section: Discussionmentioning

confidence: 96%

Concurrent maternal and fetal ovarian cysts

Francis

Heazell

Chakravorty

et al. 2010

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

Due to improvements in ultrasonography, the detection of fetal abdominal masses has increased. We describe a case of co-existing maternal and fetal ovarian cysts in a 37-year-old primiparous woman. The fetal ovarian cyst was first identified in the third trimester and reached a maximum diameter of 9 cm. The maternal cysts were present from 20 weeks onwards; with a maximum diameter of 8 cm. Histological examination showed the maternal lesions were benign dermoid cysts. The fetal lesion resolved spontaneously by 5 months. This case illustrates that fetal and maternal ovarian cysts may co-exist and could potentially have a similar hormonal etiology.

show abstract

Treatment of advanced epithelial ovarian carcinoma in pregnancy with cisplatin-based chemotherapy

Cited by 71 publications

References 10 publications

Advanced epithelial ovarian carcinoma during pregnancy

Advanced epithelial ovarian carcinoma during pregnancy

Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy

Concurrent maternal and fetal ovarian cysts

Contact Info

Product

Resources

About